2.72
4.90%
-0.14
Handel nachbörslich:
2.73
0.010
+0.37%
Schlusskurs vom Vortag:
$2.86
Offen:
$2.94
24-Stunden-Volumen:
102.23K
Relative Volume:
0.60
Marktkapitalisierung:
$133.15M
Einnahmen:
$96.63M
Nettoeinkommen (Verlust:
$-63.32M
KGV:
-1.3807
EPS:
-1.97
Netto-Cashflow:
$-54.55M
1W Leistung:
-1.81%
1M Leistung:
+6.67%
6M Leistung:
-42.00%
1J Leistung:
-41.51%
Akoya Biosciences Inc Stock (AKYA) Company Profile
Firmenname
Akoya Biosciences Inc
Sektor
Telefon
855.896.8401
Adresse
100 CAMPUS DRIVE, MARLBOROUGH
Akoya Biosciences Inc Stock (AKYA) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
2023-02-02 | Eingeleitet | UBS | Buy |
2022-11-03 | Eingeleitet | CapitalOne | Overweight |
2022-10-06 | Eingeleitet | Stephens | Overweight |
2022-06-22 | Eingeleitet | BTIG Research | Buy |
2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
2021-05-11 | Eingeleitet | Canaccord Genuity | Buy |
2021-05-11 | Eingeleitet | JP Morgan | Overweight |
2021-05-11 | Eingeleitet | Morgan Stanley | Overweight |
2021-05-11 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Akoya Biosciences Inc Aktie (AKYA) Neueste Nachrichten
Short Interest in Akoya Biosciences, Inc. (NASDAQ:AKYA) Declines By 6.4% - MarketBeat
Wall Street SWOT: Akoya Biosciences stock faces headwinds amid spatial proteomics growth By Investing.com - Investing.com South Africa
Wall Street SWOT: Akoya Biosciences stock faces headwinds amid spatial proteomics growth - Investing.com
Brokerages Set Akoya Biosciences, Inc. (NASDAQ:AKYA) Target Price at $6.56 - MarketBeat
Akoya Biosciences, Inc. (NASDAQ:AKYA) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Piper Sandler Maintains Akoya Biosciences (AKYA) Overweight Recommendation - MSN
Akoya Biosciences, Inc.'s (NASDAQ:AKYA) biggest owners are private equity firms who got richer after stock soared 18% last week - Simply Wall St
Akoya Biosciences, Inc. (NASDAQ:AKYA) Short Interest Up 6.3% in August - MarketBeat
Akoya Biosciences, Inc. (NASDAQ:AKYA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Europe, CIS & Africa Spatial Transcriptomics (Instruments, Consumables) Market Size, Share & Trends Analysis Report 2024-2030 - GlobeNewswire Inc.
Akoya Biosciences, Inc. (NASDAQ:AKYA) Sees Large Growth in Short Interest - Defense World
Akoya Biosciences, Inc. (NASDAQ:AKYA) Sees Large Increase in Short Interest - MarketBeat
Vanguard Group Inc. Has $6.82 Million Stock Position in Akoya Biosciences, Inc. (NASDAQ:AKYA) - Defense World
Akoya Biosciences (NASDAQ:AKYA) Price Target Lowered to $4.00 at Piper Sandler - Defense World
Akoya Biosciences (NASDAQ:AKYA) Price Target Lowered to $4.00 at Piper Sandler - MarketBeat
Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported, And Analysts Assigned A US$5.42 Price Target - Simply Wall St
FY2024 EPS Estimates for Akoya Biosciences, Inc. Raised by Capital One Financial (NASDAQ:AKYA) - MarketBeat
Capital One Financial Research Analysts Boost Earnings Estimates for Akoya Biosciences, Inc. (NASDAQ:AKYA) - Defense World
Akoya Biosciences Second Quarter 2024 Earnings: Revenues Disappoint - Yahoo Finance
Closing Figures: Akoya Biosciences Inc (AKYA)’s Negative Finish at 2.01, Down -6.51 - The Dwinnex
Insiders Give Up US$52k As Akoya Biosciences Stock Drops To US$2.01 - Simply Wall St
JP Morgan Downgrades Akoya Biosciences (AKYA) - MSN
Akoya Biosciences (NASDAQ:AKYA) Price Target Lowered to $7.00 at Craig Hallum - Defense World
Akoya Biosciences (NASDAQ:AKYA) Price Target Cut to $7.00 by Analysts at Craig Hallum - MarketBeat
Akoya Biosciences (NASDAQ:AKYA) Releases Quarterly Earnings Results, Hits Expectations - MarketBeat
Morgan Stanley cuts Akoya Biosciences rating on capital spend concerns - Investing.com
Akoya Biosciences (NASDAQ:AKYA) Cut to “Equal Weight” at Morgan Stanley - Defense World
A Closer Look at 4 Analyst Recommendations For Akoya Biosciences - Benzinga
BTIG cuts Akoya Biosciences stock rating amid revenue, staff concerns By Investing.com - Investing.com Australia
Akoya Biosciences (NASDAQ:AKYA) Issues Quarterly Earnings Results - Defense World
JPMorgan Chase & Co. Lowers Akoya Biosciences (NASDAQ:AKYA) to Neutral - American Banking and Market News
Akoya Biosciences (NASDAQ:AKYA) Cut to "Equal Weight" at Morgan Stanley - MarketBeat
JPMorgan Chase & Co. Lowers Akoya Biosciences (NASDAQ:AKYA) to Neutral - Defense World
Akoya Biosciences, Inc. (NASDAQ:AKYA) Q2 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Akoya Biosciences sees revenue jump, aims for break-even - Investing.com Canada
BTIG cuts Akoya Biosciences stock rating amid revenue, staff concerns - Investing.com
Akoya: Q2 Earnings Snapshot - San Antonio Express-News
Akoya stock downgraded by JPMorgan after persistent macroeconomic pressures - Investing.com
Akoya Biosciences Reports Second Quarter 2024 Financial Results - ForexTV.com
Akoya: Q2 Earnings Snapshot - The Washington Post
Akoya Biosciences, Inc. (AKYA) Q2 2024 Earnings Call Transcript - Seeking Alpha
Akoya Biosciences (AKYA) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Akoya Biosciences Reports Second Quarter 2024 Financial Results - StockTitan
Akoya Biosciences Reports Second Quarter 2024 Financial Results - GlobeNewswire
Akoya Biosciences, Inc. (NASDAQ:AKYA) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Akoya Biosciences, Inc. (NASDAQ:AKYA) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Silvercrest Asset Management Group LLC Makes New Investment in Akoya Biosciences, Inc. (NASDAQ:AKYA) - MarketBeat
Akoya Biosciences (AKYA) to Release Earnings on Monday - MarketBeat
Akoya Biosciences (AKYA) to Release Quarterly Earnings on Monday - Defense World
Akoya Biosciences stock maintains $6 price target with Buy rating at BTIG - Investing.com
Short Interest in Akoya Biosciences, Inc. (NASDAQ:AKYA) Expands By 15.6% - American Banking and Market News
Finanzdaten der Akoya Biosciences Inc-Aktie (AKYA)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):